Table 2.

Gender specific outcomes in propensity matched samples reported as rates/ 100 patient year of follow-up (95% CI) and (number of events)

	Males			Females
	Dabigatran 150 mg twice daily	Rivaroxaban 20 mg once daily	Warfarin	Dabigatran 150 mg twice daily	Rivaroxaban 20 mg once daily	Warfarin
Number of patients	7,618	7,618	7,618	11,031	11,031	11,031
Stroke	1.53 (1.31 – 1.81)(69)	0.97 (0.66 – 1.24)(48)	1.42 (1.29 – 1.77)(68)	1.44 (1.21 – 2.01) (107)	1.67 (1.20 – 2.11) (119)	1.75 (1.41 – 2.59) (130)
Any hemorrhage	3.16 (2.61 – 3.69)(142)	3.86 (3.66 – 4.48)(189)	4.23 (3.81 – 4.78) (202)	3.82 (3.10 – 4.27) (282)	5.18 (4.70 – 5.99) (327)	3.90 (3.01 – 4.36) (288)
GI hemorrhage (GIH)	2.73 (2.15 – 3.27) (123)	3.30 (3.09 – 4.01) (162)	3.24 (2.83 – 3.82) (155)	3.49 (2.88 – 3.89) (258)	4.55 (3.98 – 5.24) (288)	2.89 (2.13 – 3.61) (214)
Intra-cranial Hemorrhage (ICH)	0.13 (0.03 – (0.29)(6)	0.26 (0.08 – 0.58) (13)	0.44 (0.33 – 0.91) (21)	0.21 (0.01 – 0.33) (16)	0.38 (0.10 – 0.96) (24)	0.54 (0.37 – 1.01) (40)
Other Non-GI hemorrhage	0.49 (0.10 – 0.77) (22)	0.55 (0.15 – 0.83) (27)	1.02 (0.87 – 1.67) (49)	0.35 (0.06 – 0.51) (26)	0.66 (0.53 – 0.81) (42)	1.07 (0.90 – 1.77) (80)